Medication leaflets

Active substance

Results for the substance efmoroctocog alfa

7 results

About this active substance

Efmoroctocog alfa is a medication used to treat and prevent bleeding episodes in patients with hemophilia A, a genetic blood clotting disorder caused by factor VIII deficiency.

This medication is a modified form of factor VIII, which helps blood to clot and prevents excessive bleeding. It is administered via intravenous injection and can be used for both acute treatment and prophylaxis.

Efmoroctocog alfa is generally well-tolerated but may cause side effects such as headaches, nausea, or injection site reactions. In rare cases, severe allergic reactions or the development of inhibitors against factor VIII may occur.

It is essential to follow the treatment plan established by your doctor and to report any side effects or changes in health. Regular monitoring is necessary to ensure the treatment's effectiveness.